Journal: Molecules

Article Title: Revealing Novel Source of Breast Cancer Inhibitors from Seagrass Enhalus acoroides : In Silico and In Vitro Studies

doi: 10.3390/molecules29051082

Figure Lengend Snippet: ΔG of Molecular docking parameter of identified compounds of Seagrass E. acoroides .

Article Snippet: In vitro analysis of HIF-1α, EGFR tyrosine kinase, and HER2 Expressions was carried out in accordance with the manufacturer’s protocol (HIF-1 alpha Monoclonal Antibody (ESEE122), eBioscienceTM; Human EGFR (Epidermal Growth Factor Receptor) ELISA Kit; Elabscience ® for HER2) and established research experimental guidelines [ ].

Techniques: Control

Journal: Molecules

Article Title: Revealing Novel Source of Breast Cancer Inhibitors from Seagrass Enhalus acoroides : In Silico and In Vitro Studies

doi: 10.3390/molecules29051082

Figure Lengend Snippet: Downregulation of HIF-1A, EGFR tyrosine kinase, and HER2 by Seagrass EAE.

Article Snippet: In vitro analysis of HIF-1α, EGFR tyrosine kinase, and HER2 Expressions was carried out in accordance with the manufacturer’s protocol (HIF-1 alpha Monoclonal Antibody (ESEE122), eBioscienceTM; Human EGFR (Epidermal Growth Factor Receptor) ELISA Kit; Elabscience ® for HER2) and established research experimental guidelines [ ].

Techniques:

Journal: Journal of Personalized Medicine

Article Title: Identification of Potential microRNA Panels for Male Non-Small Cell Lung Cancer Identification Using Microarray Datasets and Bioinformatics Methods

doi: 10.3390/jpm12122056

Figure Lengend Snippet: Demographic and histopathological diagnosis of the 19 NSCLC patients used for plasma qRT-PCR validation of miR-34c-5p and miR-183-3p, and ELISA determination for EGFR, IGF-IR, and TGFβ1 from serum.

Article Snippet: Healthy subjects were detected using ELISA, with the Human EGFR DuoSet ELISA (R&D System, Minneapolis, MN, USA, cat No. DY231), Ancillary Reagent Kit 2 (R&D System, cat No. DY008), IGFIR DuoSet ELISA (R&D System, cat No. DY 391), Ancillary Reagent Kit 3 (R&D System, cat No. DY240-05), TGF beta 1 DuoSet ELISA, and Ancillary Reagent Kit 1 (R&D System, cat No. DY 007).

Techniques: Biomarker Discovery, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Journal: Journal of Personalized Medicine

Article Title: Identification of Potential microRNA Panels for Male Non-Small Cell Lung Cancer Identification Using Microarray Datasets and Bioinformatics Methods

doi: 10.3390/jpm12122056

Figure Lengend Snippet: EGFR, IGF-IR, and TGFβ1 quantification in serum of male NSCLC patients ( n = 19) and healthy subjects ( n = 34) using ELISA (** p ≤ 0.01).

Article Snippet: Healthy subjects were detected using ELISA, with the Human EGFR DuoSet ELISA (R&D System, Minneapolis, MN, USA, cat No. DY231), Ancillary Reagent Kit 2 (R&D System, cat No. DY008), IGFIR DuoSet ELISA (R&D System, cat No. DY 391), Ancillary Reagent Kit 3 (R&D System, cat No. DY240-05), TGF beta 1 DuoSet ELISA, and Ancillary Reagent Kit 1 (R&D System, cat No. DY 007).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Cancers

Article Title: Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures

doi: 10.3390/cancers13195009

Figure Lengend Snippet: TNBC tissues are represented by different patient-specific signaling signatures, majority of which do not include EGFR. ( A ) Fold changes in expression levels of EGFR and pEGFR in TNBC and non-TNBC tumors are shown. Y1068 and Y1173 are EGFR phosphorylation sites; ( B ) Examples for patient-specific sets of active unbalanced processes are shown. Each sample harbors a set of 1–3 active unbalanced processes (PaSSS), represented schematically by a barcode. In each barcode active unbalanced processes are represented by black or gray squares, inactive white. Negative/positive amplitude denotes how the patients are correlated with respect to a particular process. Suggested PaSSS-based therapies appear below each barcode; ( C ) Heterogeneity index of 3 subgroups, represented by a ratio between the number of distinct PaSSSs and the number of samples in each subset, is shown for the TNBC subset of tissues, the entire set (3467 samples from 11 cancer types) and the subset of non-TNBC samples. (Abbreviations: TNBC—Triple Negative Breast Cancer, PaSSS—Patient-specific signaling signature, EGFR—Epidermal Growth Factor Receptor, VEGFR2—Vascular Endothelial Growth Factor Receptor 2, Her2—Human Epidermal growth factor Receptor 2, Src—Proto-oncogene tyrosine-protein kinase Src).

Article Snippet: The following conjugated antibodies were used: anti-p-EGFR (Y1068) (R&D Systems, Minneapolis, MN, USA, cat. no. IC3570G), anti-p-ERK2 (Thr202/Tyr204) (BioLegend, San Diego, CA, USA, cat. No. 675503), anti-p-S6 (Ser235/236) (BioLegend, cat. no. 608605), and anti-GAPDH (Santa Cruz Biotechnology, Dallas, Texas, USA, cat. no. sc-47724AF594).

Techniques: Expressing, Phospho-proteomics